Hexagon Capital Partners LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 15.8% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,860 shares of the biopharmaceutical company’s stock after purchasing an additional 4,753 shares during the quarter. Pfizer accounts for 0.4% of Hexagon Capital Partners LLC’s holdings, making the stock its 21st largest holding. Hexagon Capital Partners LLC’s holdings in Pfizer were worth $1,422,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Moneta Group Investment Advisors LLC boosted its position in shares of Pfizer by 89,592.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after acquiring an additional 160,963,976 shares in the last quarter. Norges Bank acquired a new position in shares of Pfizer during the 4th quarter worth about $3,150,472,000. Morgan Stanley boosted its position in shares of Pfizer by 10.3% during the 4th quarter. Morgan Stanley now owns 79,499,361 shares of the biopharmaceutical company’s stock worth $4,073,547,000 after acquiring an additional 7,419,929 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Pfizer by 13.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 59,828,849 shares of the biopharmaceutical company’s stock worth $3,097,341,000 after acquiring an additional 6,972,650 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of Pfizer during the 1st quarter worth about $311,238,000. 67.80% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
Several research analysts have recently issued reports on the company. StockNews.com cut Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, June 30th. Daiwa Capital Markets cut Pfizer from an “outperform” rating to a “neutral” rating and set a $38.00 target price for the company. in a research report on Thursday, May 11th. Bank of America decreased their target price on Pfizer from $50.00 to $45.00 and set a “neutral” rating for the company in a research report on Friday, April 21st. Cantor Fitzgerald reissued an “overweight” rating on shares of Pfizer in a research report on Wednesday, May 17th. Finally, Barclays decreased their target price on Pfizer from $43.00 to $40.00 in a research report on Wednesday, May 3rd. Eleven analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, Pfizer presently has an average rating of “Hold” and an average target price of $46.67.
Insider Activity
Pfizer Stock Down 0.3 %
Pfizer stock opened at $35.53 on Friday. Pfizer Inc. has a twelve month low of $35.35 and a twelve month high of $54.93. The stock has a 50 day moving average of $38.03 and a two-hundred day moving average of $41.57. The company has a current ratio of 1.37, a quick ratio of 1.11 and a debt-to-equity ratio of 0.31. The stock has a market capitalization of $200.58 billion, a price-to-earnings ratio of 6.99, a PEG ratio of 1.18 and a beta of 0.61.
Pfizer (NYSE:PFE – Free Report) last posted its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $1.23 earnings per share for the quarter, topping analysts’ consensus estimates of $1.00 by $0.23. The company had revenue of $18.28 billion during the quarter, compared to analysts’ expectations of $16.49 billion. Pfizer had a return on equity of 37.53% and a net margin of 31.25%. The firm’s revenue for the quarter was down 28.8% on a year-over-year basis. During the same period last year, the firm earned $1.62 EPS. As a group, research analysts expect that Pfizer Inc. will post 3.35 earnings per share for the current year.
Pfizer Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 5th. Stockholders of record on Friday, July 28th will be issued a $0.41 dividend. The ex-dividend date of this dividend is Thursday, July 27th. This represents a $1.64 annualized dividend and a dividend yield of 4.62%. Pfizer’s dividend payout ratio is currently 32.28%.
Pfizer Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Articles
- Five stocks we like better than Pfizer
- MarketBeat Week in Review – 7/3 – 7/7
- Pfizer Just Invested $25 million In This Biotech
- Cracks In The Labor Market? Not Yet, But They’re Coming
- Levi’s: Buy On The Dip Or Downtrend In Play?
- Who Wins And Who Loses With China’s Metal Restrictions
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
